Long‐term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance

For BRCA1/BRCA2 gene testing to benefit public health, mutation carriers must initiate appropriate risk management strategies. There has been little research examining the long‐term use and prospective predictors of the full range of risk management behaviors among women who have undergone BRCA1/2 testing. We evaluated long‐term uptake and predictors of risk‐reducing mastectomy (RRM), risk‐reducing bilateral salpingo‐oophorectomy (RRBSO), chemoprevention, and cancer screening among women at a mean of 5.3 years after testing.

[1]  H. Valdimarsdottir,et al.  Longitudinal Changes in Patient Distress following Interactive Decision Aid Use among BRCA1/2 Carriers , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[3]  J. Philbrick,et al.  Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Sunde,et al.  Risk‐reducing mastectomy and salpingo‐oophorectomy in unaffected BRCA mutation carriers: uptake and timing * , 2010, Clinical genetics.

[5]  D. Cella,et al.  Randomized Controlled Trial of a Psychosocial Telephone Counseling Intervention in BRCA1 and BRCA2 Mutation Carriers , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[6]  Erika A. Waters,et al.  Prevalence of Tamoxifen Use for Breast Cancer Chemoprevention Among U.S. Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[7]  T. Tuttle,et al.  Patient and Surgeon Characteristics Associated with Increased Use of Contralateral Prophylactic Mastectomy in Patients with Breast Cancer , 2009, Annals of Surgical Oncology.

[8]  A. Howell,et al.  Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[9]  W. Farrar,et al.  Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer: An Increasing Trend at a Single Institution , 2009, Annals of Surgical Oncology.

[10]  T. Tuttle,et al.  Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Vittinghoff,et al.  Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. , 2009, Genetic testing and molecular biomarkers.

[12]  Jan Lubinski,et al.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers , 2008, International journal of cancer.

[13]  T. Rebbeck,et al.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Møller,et al.  Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  O. Olopade,et al.  Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers , 2008, Genetics in Medicine.

[16]  F. Couch,et al.  Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. , 2007, Clinical breast cancer.

[17]  T. Tuttle,et al.  Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[19]  R. Eeles,et al.  Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up , 2007, British Journal of Cancer.

[20]  C. Isaacs,et al.  Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors , 2006, Breast Cancer Research and Treatment.

[21]  J. Hopper,et al.  Risk‐reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study , 2006, Clinical genetics.

[22]  J. Kirk,et al.  Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. , 2006, European journal of cancer.

[23]  Rongwei Fu,et al.  Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force , 2005, Annals of Internal Medicine.

[24]  E. Legius,et al.  Surveillance Behavior and Prophylactic Surgery After Predictive Testing for Hereditary Breast/Ovarian Cancer , 2005, Behavioral medicine.

[25]  H. Nelson,et al.  Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement , 2005 .

[26]  L. V. van't Veer,et al.  Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers , 2005, British Journal of Cancer.

[27]  J. Elmore,et al.  Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[29]  C. Magnant,et al.  Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Weitzel,et al.  Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. , 2003, Archives of surgery.

[31]  C. Isaacs,et al.  Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  W. Otten,et al.  Genetic counselling and the intention to undergo prophylactic mastectomy: effects of a breast cancer risk assessment , 2003, British Journal of Cancer.

[33]  R. Croyle,et al.  Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing , 2003, American journal of medical genetics. Part A.

[34]  C. Isaacs,et al.  Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[35]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[36]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[37]  J. Satagopan,et al.  Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Isaacs,et al.  Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Chappuis,et al.  Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[40]  T. Walsh,et al.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.

[41]  T. Sellers,et al.  Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. d'Agincourt-Canning.  Experiences of genetic risk: disclosure and the gendering of responsibility. , 2001, Bioethics.

[43]  J. Andersen,et al.  Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. , 2000, American journal of surgery.

[44]  R. Croyle,et al.  Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. , 2000, Preventive medicine.

[45]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[46]  J. Dungan.  Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality , 2011 .

[47]  Suzanne O'Neill,et al.  Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. , 2009, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[48]  S. Narod,et al.  The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation , 2005, Familial Cancer.

[49]  H. Nelson,et al.  Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: evidence synthethis , 2005 .

[50]  J O Barentsz,et al.  Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. , 2001, Journal of the National Cancer Institute.